Swapna Amod Patankar
Bharati Vidyapeeth Deemed University, India
Title: Evaluation of the incidence of co-infections of Hepatitis B and/or Hepatitis C in HIV seropositive patients and the effect of Highly Active Anti-retroviral Therapy (HAART) on liver functions and presence of oral mucosal pathologies
Biography
Biography: Swapna Amod Patankar
Abstract
Human Immunodeficiency Virus (HIV) infection causes the acquired immunodeficiency syndrome (AIDS) which is now recognized as the great pandemic of the second half of the twenty first century. Approximately 37.7 million people are living with HIV at the end of 2020 (global statistics). As per the latest HIV estimates report (2019) of the Government India is estimated to have around 23.49 lakh people living with HIV/AIDS (PLHIV) in 2019. The HIV epidemic has an overall decreasing trend in country with estimated annual new HIV infections declining by 37% between 2010 and 2019. Hepatitis B co-infection with Human Immunodeficiency Virus (HIV) is associated with accelerated progression to cirrhosis and thus a higher mortality. These viruses are the most common chronic viral infections all over the world and they share similar routes of transmission with sexual, parenteral and perinatal transmission being the most frequent modes of acquiring these infections, hence HIV-HBV co-infections are common. While HIV is Ribonucleic Acid (RNA) viruses and HBV is a Deoxyribonucleic Acid (DNA) virus; but they are similar in terms of how high they replicate in the body. HAART (Highly Active Anti-retroviral Therapy) has extended the life expectancy of people with HIV, but liver diseases related to HCV and HBV complicate management of HAART, which is a leading cause of non-AIDS[1]related deaths in this population. Prevalence of HCV & HBV co-infections in HIV patients in the world. According to WHO (World Health Organization). HIV-HBV co-infection: 7.6%.